Catch up on the top radiology content of the past week.
|Articles|March 1, 2000
Radiologix continues revenue climb
Radiology services provider Radiologix continues to outpace analysts’ revenue expectations but is still struggling, stockwise. The firm reported revenues of $51.7 million for the fourth quarter (end-December), marking the company’s ninth
Advertisement
Radiology services provider Radiologix continues to outpace analysts revenue expectations but is still struggling, stockwise. The firm reported revenues of $51.7 million for the fourth quarter (end-December), marking the companys ninth consecutive quarter of revenue growth. Net income for the quarter was $4 million, compared to net income of $3.7 million on revenues of $37.3 million for the same quarter a year ago. Revenues for the year totaled $181 million, a 33% increase over revenues of $135.6 million in 1998. Net income for the quarter rose 19% to $16 million from $13.5 million in 1998.
Despite the increases, the companys stock continues to hover around $4 per share. The stock reached its peak of nearly $9 per share last September following Radiologixs acquisition of Questar (SCAN 8/18/99). That deal made Radiologix (then known as American Physician Partners) one of the largest operators of imaging centers in the U.S., with 118 sites in 18 states and the District of Columbia.
In related news, Radiologix named former senior vice president and COO Mark Martin president of the Dallas-based company. Martin takes over from Mark Wagar, who continues to serve as chairman and CEO.
Advertisement
Related to this article
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Emerging Research Insights and New Advances in Neuroradiology
2
MRI, CT or Ultrasound: Which Modality Offers the Most Utility for Imaging of Pancreatic Cancer?
3
Diagnostic Imaging's Weekly Scan: September 27 — October 3
4
FDA Grants Fast Track Designation for Pre-Biopsy Use of PSMA PET and MRI for Prostate Cancer Detection
5